EVT 302, 10 mg + placebo + Nicotine replacement therapy (NRT)

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Smoking Cessation

Conditions

Smoking Cessation

Trial Timeline

Feb 1, 2008 → May 1, 2008

NCT ID

NCT00622752

About EVT 302, 10 mg + placebo + Nicotine replacement therapy (NRT)

EVT 302, 10 mg + placebo + Nicotine replacement therapy (NRT) is a phase 2 stage product being developed by Evotec for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT00622752. Target conditions include Smoking Cessation.

What happened to similar drugs?

12 of 20 similar drugs in Smoking Cessation were approved

Approved (12) Terminated (0) Active (8)

🔄Nicotine gum + Placebo gum + Nicotine inhaler + Placebo inhalerJohnson & JohnsonPhase 3

✅Nicotine patch, nicotine inhaler, bupropion + Nicotine patchJohnson & JohnsonApproved

🔄placebo + Varenicline TartaratePfizerPhase 3

✅varenicline + placeboPfizerApproved

🔄varenicline (CP-526,555)PfizerPhase 3

✅placebo + vareniclinePfizerApproved

🔄Varenicline + BupropionPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00622752	Phase 2	Completed	Feb 1, 2008	May 1, 2008	Smoking Cessation

Competing Products

20 competing products in Smoking Cessation

See all competitors

Product	Company	Stage	Hype Score
Brenipatide + Placebo	Eli Lilly	Phase 2	42
Nicotine + Nicotine + Nicotine	Johnson & Johnson	Phase 2	35
Nicotine replacement therapy + Nicotine replacement therapy	Johnson & Johnson	Phase 2	35
Nicotine Patch + Placebo Patch	Johnson & Johnson	Phase 1	29
Nicotine Patch + Placebo Patch + SLS Comparator Patch	Johnson & Johnson	Phase 1	29
Nicotine + Placebo	Johnson & Johnson	Pre-clinical	26
Nicotine Patch + Nicotine Patch Comparator + Placebo Patch	Johnson & Johnson	Phase 1	29
Nicotine Patch + Placebo Patch + No Patch Control	Johnson & Johnson	Phase 1	29
Nicotine gum + Placebo gum + Nicotine inhaler + Placebo inhaler	Johnson & Johnson	Phase 3	40
Nicotine patch, nicotine inhaler, bupropion + Nicotine patch	Johnson & Johnson	Approved	43
AZD4041 + Placebo	AstraZeneca	Phase 1	29
taranabant	Merck	Phase 2	35
Nicotine replacement therapy	Novartis	Pre-clinical	22
AFQ065	Novartis	Phase 1	29
Liraglutide + Placebo	Novo Nordisk	Phase 2	35
Varenicline	Pfizer	Phase 2	35
placebo + Varenicline Tartarate	Pfizer	Phase 3	40
varenicline + placebo	Pfizer	Approved	39
varenicline (CP-526,555)	Pfizer	Phase 3	40
placebo + varenicline	Pfizer	Approved	43